DESTINY-Gastric05 Phase III Trial of Enhertu (trastuzumab deruxtecan) initiated in patients with previously untreated HER2 Positive advanced gastric cancer – Daiichi Sankyo
The first patient has been dosed in the DESTINY-Gastric05 phase IIII trial evaluating Enhertu (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Merck’s anti-PD-1… read more.

